Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse, der sammenligner Siplizumab med kanin anti-thymocytglobulin for at hjælpe kroppen med at acceptere en nyretransplantation (MODERNIZE1)

6. november 2026 opdateret af: ITB-Med LLC

Fase 2b, randomiseret, multicenter, dobbeltblind, dosisfindingsstudie af Siplizumab (TCD601) sammenlignet med kanin anti-thymocytglobulin hos nyretransplantationsmodtagere, der kræver induktionsterapi og modtager standardimmunsuppression med tacrolimus, mycofenolsyre og kortikosteroider

The goal of this clinical trial is to learn if siplizumab can prevent rejection of a kidney transplant in adult participants with end stage kidney disease. The main questions it aims to answer are:

How many adverse events do participants receiving two different doses of siplizumab have compared to rabbit anti-thymocyte globulin (rATG)?

How many participants successfully keep their kidney transplant after receiving siplizumab or rATG? This will be calculated as those participants that did not: die; have their kidney fail to work properly (graft loss); their body rejects their transplant (tissue sample (biopsy)-proven acute rejection: BPAR); or who were lost to follow-up.

How does the body respond to siplizumab after dosing at each of the 2 dose levels?

How does siplizumab work in the body compared to rATG?

Selected participants will be divided into 3 groups. In 2 of the groups, participants will be given siplizumab at one of the two study medicine doses. Participants in the third group will be given rATG. All participants will take the usual anti-rejection medicines given before, during, and after a kidney transplant. All participants will also be given medicines before the study drug to lower the risk of reactions, and medicines used to prevent or treat infections after the transplant.

Participants will be asked to provide their medical history at the first visit at the study site where you will have your kidney transplant. At the first visit and other visits participants will be asked to provide their medication history, have a physical exam, check vital signs, have blood drawn for tests, and have non-invasive tests that record the electrical activity of your heart (ECG) and blood draws.

Participants will be monitored for 12 months after transplant surgery.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Approximately 120 renal transplant candidates requiring induction therapy will be enrolled 1:1:1 to receive 1 of 2 dose levels of siplizumab or to the comparator rATG.

Randomization will be stratified by donor status (living vs donation after brain death vs donation after cardiac death) to ensure similar proportions of donor types in each study arm. All participants will also receive:

  • A triple regimen (TAC, MPA, and CS) of background immunosuppressive therapy for the duration of the study.
  • Premedication prior to study treatment infusions.
  • Infection prophylaxis

This clinical trial will evaluate the safety of an anti-cluster of differentiation 2 (CD2) monoclonal antibody, siplizumab, compared to rATG as induction therapy in renal transplant recipients.

Following hospital discharge, participants will undergo assessments and procedures as indicated in the protocol through Month 12 or EOS, unless more frequent visits are required per local SoC or for laboratory specimen collection.

Safety assessments will include physical examinations, ECGs, vital signs, viral surveillance and monitoring, standard clinical laboratory evaluations completed centrally (hematology, clinical chemistry, urinalysis), and AE/SAE monitoring.

Final analysis will be performed when all participants have completed 12-month follow-up visits post-transplant or have otherwise ended the trial. This analysis will be performed to evaluate the safety of siplizumab at 2 dose levels compared to rATG.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

120

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Minas Gerais
      • Belo Horizonte, Minas Gerais, Brasilien, 30150-320
        • Rekruttering
        • Santa Casa Demisericordia de Belo Horizonte
        • Kontakt:
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasilien, 90035-903
        • Rekruttering
        • Hospital de Clinicas de Porto Alegre
        • Kontakt:
      • Porto Alegre, Rio Grande do Sul, Brasilien, 90020-090
        • Rekruttering
        • Santa Casa de Misericordia de Porto Alegre - Hospital Dom Vincente Scherer
        • Kontakt:
    • São Paulo
      • São José do Rio Preto, São Paulo, Brasilien, 15090-000
        • Rekruttering
        • Fundação Faculdade Regional de Medicina de São José do Rio Preto - Centro Integrado de Pesquisa
        • Kontakt:
      • São Paulo, São Paulo, Brasilien, 04038-002
        • Rekruttering
        • Fundação Oswaldo Ramos - Hospital do Rim (HRIM)
        • Kontakt:
    • California
      • Los Angeles, California, Forenede Stater, 90033
        • Rekruttering
        • Keck Hospital of the University of Southern California
        • Kontakt:
      • Los Angeles, California, Forenede Stater, 90095
        • Rekruttering
        • University of California - Los Angeles, Connie Frank Kidney Transplant Center
        • Kontakt:
      • Sacramento, California, Forenede Stater, 95817
        • Rekruttering
        • UC Davis Medical Center
        • Kontakt:
    • Florida
      • Tampa, Florida, Forenede Stater, 33606
        • Rekruttering
        • Tampa General Hospital
        • Kontakt:
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30322
        • Rekruttering
        • Emory University Hospital
        • Kontakt:
    • Kansas
      • Kansas City, Kansas, Forenede Stater, 66160
        • Rekruttering
        • University of Kansas Hospital
        • Kontakt:
    • Kentucky
      • Lexington, Kentucky, Forenede Stater, 40536
        • Rekruttering
        • University of Kentucky Healthcare
        • Kontakt:
    • Louisiana
      • Metairie, Louisiana, Forenede Stater, 70006
        • Rekruttering
        • Tulane Medical Center
        • Kontakt:
    • Massachusetts
      • Worcester, Massachusetts, Forenede Stater, 01655
    • Michigan
      • Ann Arbor, Michigan, Forenede Stater, 48109
        • Rekruttering
        • University of Michigan - Michigan Medicine
        • Kontakt:
          • Nerissa Reister, Clinical Research Coordinator
          • Telefonnummer: 734-763-5718
          • E-mail: naflow@med.umich.edu
      • Detroit, Michigan, Forenede Stater, 48202
        • Rekruttering
        • Henry Ford Health
        • Kontakt:
    • New Jersey
      • Livingston, New Jersey, Forenede Stater, 07039
        • Rekruttering
        • Cooperman Barnabus Medical Center
        • Kontakt:
    • New York
      • New York, New York, Forenede Stater, 10032
        • Rekruttering
        • New York Presbyterian - Columbia University Irving Medical School
        • Ledende efterforsker:
          • Lloyd Ratner, MD
        • Kontakt:
        • Kontakt:
      • New York, New York, Forenede Stater, 10065
        • Rekruttering
        • New York Presbyterian - Weill Cornell Medical Center
        • Kontakt:
        • Kontakt:
    • North Carolina
      • Durham, North Carolina, Forenede Stater, 27710
        • Rekruttering
        • Duke University Medical Center
        • Kontakt:
    • Texas
      • Dallas, Texas, Forenede Stater, 75390
    • Virginia
      • Falls Church, Virginia, Forenede Stater, 22042
        • Rekruttering
        • Inova Fairfax Hospital
        • Kontakt:
      • Richmond, Virginia, Forenede Stater, 23298
        • Rekruttering
        • Virginia Commonwealth University Health
        • Kontakt:
    • Washington
      • Seattle, Washington, Forenede Stater, 98195
        • Rekruttering
        • University of Washington Medical Center
        • Kontakt:
          • Belinda Pan, Research Coordinator
          • Telefonnummer: 206-598-1562
          • E-mail: bcpan@uw.edu
      • Barcelona, Spanien, 08035
        • Rekruttering
        • Hospital Universitari Vall D'Hebron
        • Kontakt:
      • Córdoba, Spanien, 14004
      • Málaga, Spanien, 29010
        • Rekruttering
        • Hospital Universitario Regional de Malaga
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 70 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Recipients of a renal allograft from a non-HLA identical living or deceased donor.
  • Recipients of a kidney with a cold ischemia time < 30 hours; hypothermic machine perfusion within the same timeframe is acceptable.
  • Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, must agree to use highly effective methods of contraception.

Exclusion Criteria:

  • Transplant recipients seronegative for EBV.
  • Transplant recipients receiving a kidney from a non-heart beating donor (ie, DCD) whose organ is retrieved from an uncontrolled DCD or whose donor age > 55 years of age.
  • Multi-organ transplant recipients (eg, kidney-pancreas, organ other than kidney), dual-kidney transplant recipients, recipients with more than one prior kidney transplant, or hematopoietic stem cell transplantation recipients.
  • Presence of current or historical DSA via single-antigen bead assay or local SoC. The MFI cut-off value used to determine the presence of DSA will be defined as per the institutional SoC. Results within 3 months prior to transplant are acceptable.
  • Crossmatch positive (isolated positive B cell crossmatches are not an exclusion criterion).
  • ABO-incompatible recipient.
  • Administration of complement inhibitor therapy within 6 months prior to the transplant, or likely to require treatment with complement inhibitor therapy during the study.
  • Participants receiving immunosuppressive therapies prior to transplant for pre-existing conditions must be candidates for the protocol-defined regimen.
  • History of malignancy of any organ system, except for localized excised non-melanomatous skin lesions or carcinoma in situ of the cervix.
  • Seropositive for human immunodeficiency virus or hepatitis B surface antigen. Participants who are seropositive for hepatitis C virus (HCV) are excluded without proof of sustained viral response after anti-HCV treatment.
  • Recipient of a kidney from a donor who tests positive for human immunodeficiency virus or hepatitis B surface antigen/hepatitis B core protein.
  • History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes (eg, siplizumab, rATG, TAC, MPA derivatives, CS).
  • Evidence of active tuberculosis (TB) infection (participants with a history of latent TB may become eligible after treatment with anti-TB therapy according to national guidelines).
  • Participants with severe systemic infection(s), at the time of screening or within 2 weeks prior to randomization

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Lav dosis siplizumab

A non-agonistic, humanized, anti-CD2 monoclonal antibody of the IgG1κ class

Andre navne:
  • TCD601
Eksperimentel: Høj dosis siplizumab

A non-agonistic, humanized, anti-CD2 monoclonal antibody of the IgG1κ class

Andre navne:
  • TCD601
Aktiv komparator: Kanin anti-thymocyt globulin

An anti-human thymocyte immunoglobulin preparation made of purified polyclonal antibodies derived from rabbits

Andre navne:
  • Thymoglobulin

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Assessment of the safety of 2 dose levels of siplizumab versus rATG.
Tidsramme: 12 months

Number and percentage of participants at 12 months post-transplant experiencing adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs).

12 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Tidsramme: 12 months
  • Composite incidence of BPAR, death, graft loss, and loss-to-follow-up.
  • Incidence of participants who experienced BPAR as defined by central pathology (blinded independent central review using Banff Allograft Pathology Scoring).
  • Incidence of treated BPAR and steroid-resistant BPAR.
12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Tidsramme: 12 months

• Grade of BPAR.

12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Tidsramme: 12 months

• Severity of BPAR.

12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Tidsramme: 12 months
  • Time to first BPAR for each participant.
  • Time to graft loss for each participant.
  • Time to death for each participant.
12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Tidsramme: 12 months
  • Participant survival at 12 months.
  • Graft survival at 12 months.
12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Tidsramme: 12 months

• Number of participants requiring for-cause renal allograft biopsy assessments over 12 months post-transplant.

12 months
Assessment of the pharmacokinetics (PK) of 2 dose levels of siplizumab.
Tidsramme: 12 weeks

Siplizumab Cmax (maximum blood concentration) over 12 weeks post-transplant.

12 weeks
Assessment of the pharmacokinetics (PK) of 2 dose levels of siplizumab.
Tidsramme: 12 weeks

Siplizumab AUC (area under the concentration-time curve) over 12 weeks post-transplant.

12 weeks
Assessment of the pharmacodynamics (PD) of 2 dose levels of siplizumab versus rATG.
Tidsramme: 12 months

Depletion and recovery of lymphocyte count by subset (total lymphocytes; CD3+, CD4+, and CD8+ T cells; CD19+ B cells; CD56+ NK cells) over 12 months post-transplant.

12 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

29. juni 2026

Primær færdiggørelse (Anslået)

28. marts 2028

Studieafslutning (Anslået)

28. marts 2028

Datoer for studieregistrering

Først indsendt

11. marts 2026

Først indsendt, der opfyldte QC-kriterier

27. marts 2026

Først opslået (Faktiske)

2. april 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

12. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

6. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • TCD601B205

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .